Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,384 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Adenocarcinoma Clear all
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Liver Cancer

NCT00022334
View directory record Official record
Conditions
Liver Cancer
Interventions
AFP
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

NCT00006371
View directory record Official record
Conditions
Prostate Cancer
Interventions
aminoglutethimide, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer

NCT00006786
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
74
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00368992
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cetuximab, paclitaxel, bevacizumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

NCT00866320
View directory record Official record
Conditions
Kidney Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00257426
View directory record Official record
Conditions
Liver Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110
View directory record Official record
Conditions
Mucinous Gastrointestinal Adenocarcinoma
Interventions
cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

NCT00091026
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
cetuximab, gemcitabine hydrochloride, bevacizumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 19, 2026, 9:06 AM EDT
Not listed Phase 2 Interventional

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

NCT00003326
View directory record Official record
Conditions
Esophageal Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
30
States / cities
Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385
View directory record Official record
Conditions
Ovarian Cancer, Merkel Cell Carcinoma, SCLC
Interventions
BB-10901
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
6
States / cities
San Francisco, California • Las Vegas, Nevada • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00735917
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
saracatinib, pharmacogenomic studies, pharmacological study, positron emission tomography, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206
View directory record Official record
Conditions
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions
zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
503
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01011933
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Selumetinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
72
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

NCT01331135
View directory record Official record
Conditions
Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Ependymoma, Germ Cell Tumor, Glioma, Medulloblastoma, Rhabdoid Tumor, Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01266447
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
78
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 19, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00438204
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, gemcitabine hydrochloride, pemetrexed disodium
Biological · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed disodium, sorafenib tosylate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
207
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 19, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

NCT03219372
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cirrhoses
Interventions
Pravastatin Pill, Placebo Oral Tablet
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 19, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

NCT04805788
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8
Interventions
Proton Stereotactic Body Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, flutamide, ketoconazole, paclitaxel, releasing hormone agonist therapy, vinblastine sulfate
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00044291
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-dependent
Interventions
atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
17
States / cities
Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 19, 2026, 9:06 AM EDT